LONG TERM FOLLOW-UP OF NEOADJUVANT-ADJUVANT COMBINATION TREATMENT OF IIIA STAGE NON-SMALL-CELL-LUNG CANCER:RESULTS OF NEOADJUVANT CARBOPLATIN/VINORELBINE AND CARBOPLATIN/PACLITAXEL REGIMENS COMBINED WITH SELECTIVE ADJUVANT CHEMOTHERAPY
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F08%3A00006219" target="_blank" >RIV/61989592:15110/08:00006219 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
LONG TERM FOLLOW-UP OF NEOADJUVANT-ADJUVANT COMBINATION TREATMENT OF IIIA STAGE NON-SMALL-CELL-LUNG CANCER:RESULTS OF NEOADJUVANT CARBOPLATIN/VINORELBINE AND CARBOPLATIN/PACLITAXEL REGIMENS COMBINED WITH SELECTIVE ADJUVANT CHEMOTHERAPY
Original language description
Background: A prospective study investigated survival of patients with stage IIIA non-small-cell-lung cancer (NSCLC) treated with a combination of neoadjuvant and adjuvant chemotherapy. Methods: Consecutive chemo-naive patients with potentially operablestage IIIA NSCLC received carboplatin-based neoadjuvant treatment. Tumor cells harvested during surgery underwent methylthiazolyl tetrazolium blue (MTT) cytotoxic assay. After surgery, adjuvant chemotherapy was selected, where possible, according to MTTresults. Results: A total of 65 patients were evaluated (31 received carboplatin/vinorelbine, 34 carboplatin/paclitaxel). The overall response rate was 67.7 % (95% confi dence interval [CI]: 56.3?79.1 %) with downstaging in 52.3 % (95% CI: 40.2?64.5 %) and no signifi cant diff erences between regimens. Median follow-up was 86 months: median overall survival (OS) was 32.1 months (95% CI: 7.4?46.5), median time to progression was 25.1 months (95% CI: 15.1?34.9 months) and five year overall
Czech name
Dlouhodobé sled. kombinace neoadjuvantní a adjuvantní léčby u st. IIIA nemalobun. karc. plic: Výsledky neoadjuvantních režimů karboplatina/vinorelbin a karboplatina/paklitaxel kombin. se selekt.adjuvantní chermoterapií
Czech description
Je sledován soubor 65 pacientů, kteří byli léčeni uvedenou kombinací. Medián sledování byl 86 měsíců, medián přežití celého souboru 32,1 měsíců. Operováno bylo 72,3% nemocných. Medián přežití operovanýcz byl 59,0 meséců a medián přežití léčených podle testu in-vitro rezistence byl 85,1 mesíců. Efektivita i tolerance obou použitých neoadjuvantních režimů byly srobnatelné.
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FC - Pneumology
OECD FORD branch
—
Result continuities
Project
—
Continuities
Z - Vyzkumny zamer (s odkazem do CEZ)
Others
Publication year
2008
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Biomedical Papers
ISSN
1213-8118
e-ISSN
—
Volume of the periodical
152
Issue of the periodical within the volume
2
Country of publishing house
CZ - CZECH REPUBLIC
Number of pages
8
Pages from-to
—
UT code for WoS article
—
EID of the result in the Scopus database
—